Article | Published:

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

Abstract

The structure of unliganded HIV-1 reverse transcriptase has been determined at 2.35 Å resolution and refined to an R-factor of 0.219 (for all data) with good stereochemistry. The unliganded structure was produced by soaking out a weak binding non-nucleoside inhibitor, HEPT, from pregrown crystals. Comparison with the structures of four different RT and non-nucleoside inhibitor complexes reveals that only minor domain rearrangements occur, but there is a significant repositioning of a three-stranded β-sheet in the p66 subunit (containing the catalytic aspartic acid residues 110, 185 and 186) with respect to the rest of the polymerase site. This suggests that NNIs inhibit RT by locking the polymerase active site in an inactive conformation, reminiscent of the conformation observed in the inactive p51 subunit.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Baba, M. et al. Highly specific inhibition of human immunodeficiency virus type-1 by a novel 6-substituted acyclouridine derivative. Biochem. biophys. Res. Commun. 165, 1375–1381 (1989).

  2. 2

    Pauwels, R. et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470–474 (1990).

  3. 3

    Merluzzi, V.J. et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250, 1411–1413 (1990).

  4. 4

    De Clercq, E. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13, 229–258 (1993).

  5. 5

    Wu, J.C. et al. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry 30, 2022–2026 (1991).

  6. 6

    Debyser, Z. et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5 1-jk][1,4] benzodiazepin-2(1H)-oneand -thione derivatives. Proc. natn. Acad. Sci. U.S.A. 88, 1451–1455 (1991).

  7. 7

    Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783–1790 (1992).

  8. 8

    Smerdon, S.J. et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficency virus type 1. Proc. natn. Acad. Sci. U.S.A. 91, 3911–3915 (1994).

  9. 9

    Ren, J.S. et al. High resolution structure of HIV-1 RT: insights from four RT-inhibitor complexes. Nature struct. Biol. 2, 293–302 (1995).

  10. 10

    Tantillo, C. et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. molec. Biol. 243, 369–387 (1994).

  11. 11

    Stammers, O.K. et al. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J. molec. Biol. 242, 586–588 (1994).

  12. 12

    Debyser, Z. et al. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds. Molec. Pharmacol. 41, 203–208 (1992).

  13. 13

    Bakhanashvili, M. & Hizi, A. Interaction of the reverse transcriptase of human immunodeficiency virus type 1 with DNA. Biochemistry 33, 12222–12228 (1994).

  14. 14

    Divita, G. etal. Kinetics of interaction of HIV reverse transcriptase with primer/template. Biochemistry 32, 7966–7971 (1993).

  15. 15

    Sakabe, N. X-ray diffraction data collection system for modern protein crystallography with a Weissenberg camera and an imaging plate using synchrotron radiation. Nucl. Instr. Meths phys. Res. 303, 448–463 (1991).

  16. 16

    Stuart, D.I. & Jones, E.Y. Weissenberg data collection for macromolecular crystallography. Curr. Opin. struct. Biol. 3, 737–740 (1993).

  17. 17

    Otwinowski, Z., Oscillation data reduction program, in Data collection and Processing (L. Sawyer, N. Isaacs, S. Bailey, Eds.) pp. 56–62 (SERC Daresbury Laboratory, Warrington, England, 1993).

  18. 18

    Brünger, A.T., X-PLOR Manual V. 3.1. (Yale University, New Haven, CT; 1992).

  19. 19

    Jones, T.A. Interactive computer graphics: FRODO. Meths. Enzymol. 115 157–171 (1985).

  20. 20

    Brünger, A.T., Krukowski, A. & Erickson, J. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta crystallogr. A46, 585–593 (1990).

  21. 21

    Brünger, A.T. Extension of molecular replacement: a new search strategy based on Patterson correlation coefficient refinement. Acta crystallogr. 46, A46–57 (1990).

  22. 22

    Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta. crystallogr. A47, 110–119 (1991).

  23. 23

    Kraulis, P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. appl. Crystallogr. 24, 946–950 (1991).

  24. 24

    Merritt, E.A. & Murphy, M.E.P. Raster3D version 2.0 Å program for photorealistic molecular graphics. Acta crystallogr. D50, 869–873 (1994).

  25. 25

    Spence, R.A. Kati, W.M. Anderson, K.S. & Johnson, K.A. Science 267, 988–993 (1995).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading